Clinical Validity of FoundationOne Liquid CDx for Detection of <i>BRAF</i> V600E in Colorectal Cancer
In the phase III BEACON trial, which established Enco plus Cetux as a standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer, mutational status was confirmed through testing of tumor tissue. To support rapid, less invasive testing for BRAFV600E in plasma, this retrospective study assessed a ctDNA-based assay and found strong concordance between the liquid biopsy test and the tumor-based assay in detecting BRAFV600E.
Authors
- Lincoln W. Pasquina (ORCID: https://orcid.org/0009-0009-5461-9777)
- Shibing Deng (ORCID: https://orcid.org/0000-0002-2867-263X)
- Jean-François Martini (ORCID: https://orcid.org/0000-0001-8570-1401)
- Scott Kopetz (ORCID: https://orcid.org/0000-0001-9647-3416)
- Xiaosong Zhang
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- Brian Tunquist (ORCID: https://orcid.org/0009-0001-9897-2806)
- Rona Yaeger (ORCID: https://orcid.org/0000-0002-7233-5454)
- James M. Kiely
- Ta-Chou Vincent Ng (ORCID: https://orcid.org/0000-0003-1446-5864)
- Norberto Pantoja Galicia (ORCID: https://orcid.org/0000-0001-8614-5216)
- Cui Guo (ORCID: https://orcid.org/0000-0002-3297-119X)
- Graham Ferrier
- Siliang Gong (ORCID: https://orcid.org/0009-0002-8012-9551)
- Fatima Khaiser
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Pfizer (United States) (US)
- Boston Foundation (US)
- Emergency Medicine Foundation (US)
- Flometrics (United States) (US)
- Daiichi Sankyo (United States) (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0002
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Pfizer
- Array BioPharma
- National Institutes of Health
- National Cancer Institute